Pseudomonas aeruginosa serious infections: mono or combination antimicrobial therapy?

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Pseudomonas aeruginosa (P. aeruginosa) causes severe infections with high mortality rates (up to 61%).
• Inappropriate antimicrobial treatment is linked to increased hospital mortality in P. aeruginosa bloodstream infections.
• Rising antimicrobial resistance complicates empirical therapy selection for P. aeruginosa, often indistinguishable from other Gram-negative bacteria.

Purpose of the Study:

• To review the advantages and disadvantages of combination therapy versus monotherapy for severe P. aeruginosa infections.
• To discuss current antibiotics used for P. aeruginosa severe infections.
• To summarize key studies on P. aeruginosa treatment strategies.

Main Methods:

• Literature review of studies on P. aeruginosa bloodstream infections.
• Analysis of current treatment guidelines and consensus recommendations.
• Evaluation of empirical combination therapy versus monotherapy.

Main Results:

• Guidelines recommend prompt empirical antimicrobial therapy including antipseudomonal agents for suspected P. aeruginosa bacteremia.
• Empirical combination therapy is favored to balance toxicity against reduced resistance emergence and potential synergistic killing.
• The review covers current antibiotics and major studies relevant to P. aeruginosa treatment.

Conclusions:

• Rapid initiation of effective antimicrobial therapy is critical for managing P. aeruginosa bloodstream infections.
• Combination therapy presents a strategy to enhance efficacy and mitigate resistance, though toxicity must be considered.
• Further research and adherence to guidelines are essential for optimizing patient outcomes.